Skip to main
ARGX
ARGX logo

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 61%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Argenx has demonstrated impressive financial growth, with Vyvgart revenues reaching $790 million in Q1 2025, reflecting a 98% year-over-year increase, and $949 million in Q2 2025, a 97% increase year-over-year, driven by rising adoption in generalized myasthenia gravis (gMG) and expanding traction in chronic inflammatory demyelinating polyneuropathy (CIDP). The approval of the pre-filled syringe (PFS) format significantly enhanced growth, with approximately 1,000 PFS prescribers reported and 150 new prescribers entering the market, indicating strong potential for continued expansion. Furthermore, ongoing label expansion opportunities and positive trial results from the Phase Ib DOK7-CMS study bolster the company's innovative pipeline, enhancing the outlook for future revenue growth from both existing and new indications.

Bears say

Argenx faces significant risks that contribute to a negative outlook for its stock, primarily due to concerns over lower-than-expected growth in sales of its lead product, Vyvgart. The company is also currently navigating ongoing clinical trials for efgartigimod and empasiprubart, which could be adversely affected by unforeseen safety signals or competitive pressures. Additionally, broader macroeconomic factors such as currency fluctuations, inflation, and potential shipping risks pose further challenges to Argenx’s operational stability and profitability.

argenx (ARGX) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 61% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 18 analysts, argenx (ARGX) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $962.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $962.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.